We demonstrated through qRT-PCR and immunohistochemistry that MDK is highly expressed in HCC cells, which suggests that MDK has a potential to become a new therapeutic target in the near future, providing a new method of clinical treatment. This evidence concerns the gene MDK and hepatocellular carcinoma.